Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

Genentech announced positive results from the Phase III ALLEGORY study of Gazyva in adults with systemic lupus erythematosus (SLE) on standard therapy...
Home/KnloSights/Clinical Trial Updates/Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus